Carl Kraus Sells 20,272 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock

Key Points

• Carl Kraus, an insider at Aquestive Therapeutics, sold 20,272 shares at $7.00 each, reducing his stake by 6.70% to approximately 282,475 shares valued at $1.98 million.
• Aquestive Therapeutics reported an earnings per share of ($0.14) for the last quarter, beating estimates, with revenue of $10 million, slightly below the expected $11.32 million.
• Equities analysts have generally positive views on the stock, with upgrades from Oppenheimer and JMP Securities, and an average target price of $10.71, indicating a potential for growth.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Carl Kraus sold 20,272 shares of the firm's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $7.00, for a total value of $141,904.00. Following the completion of the transaction, the insider owned 282,475 shares in the company, valued at approximately $1,977,325. This represents a 6.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Aquestive Therapeutics Trading Up 1.0%

Aquestive Therapeutics stock traded up $0.07 during mid-day trading on Friday, hitting $7.08. The stock had a trading volume of 3,309,585 shares, compared to its average volume of 1,911,560. The stock has a 50-day simple moving average of $5.00 and a two-hundred day simple moving average of $3.81. The stock has a market capitalization of $706.02 million, a PE ratio of -10.11 and a beta of 1.77. Aquestive Therapeutics, Inc. has a 12 month low of $2.12 and a 12 month high of $7.51.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Oppenheimer raised their target price on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a report on Monday, September 8th. JMP Securities lifted their price objective on Aquestive Therapeutics from $9.00 to $12.00 and gave the company a "market outperform" rating in a report on Thursday, October 9th. Lifesci Capital upgraded Aquestive Therapeutics to a "strong-buy" rating in a report on Wednesday, September 3rd. Citigroup reiterated an "outperform" rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Finally, Zacks Research raised Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $10.71.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Trust Point Inc. acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $126,000. Cox Capital Mgt LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $59,000. Modern Wealth Management LLC acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $33,000. BNP Paribas Financial Markets increased its position in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock worth $31,000 after purchasing an additional 4,134 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $217,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.